BlackRock’s Ensysce Biosciences ENSC Stock Holding History

BlackRock’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19	Hold	65	–	–	﹤0.01%	5659
2026 Q1	$35	Hold	65	–	–	﹤0.01%	5639
2025 Q4	$60	Hold	65	–	–	﹤0.01%	5484
2025 Q3	$154	Hold	65	–	–	﹤0.01%	5393
2025 Q2	$145	Hold	65	–	–	﹤0.01%	5405
2025 Q1	$166	Buy	65 +1	+2%	+$6	﹤0.01%	5373
2024 Q4	$521	Sell	64 -1	-2%	-$7	﹤0.01%	5326
2024 Q3	$234	Hold	65	–	–	﹤0.01%	5173
2024 Q2	$494	Hold	65	–	–	﹤0.01%	5219
2024 Q1	$770	Hold	65	–	–	﹤0.01%	5212
2023 Q4	$1.03K	Hold	65	–	–	﹤0.01%	5267
2023 Q3	$1.35K	Hold	65	–	–	﹤0.01%	5314
2023 Q2	$1.75K	Hold	65	–	–	﹤0.01%	5376
2023 Q1	$4.74K	Hold	65	–	–	﹤0.01%	5375
2022 Q4	$8.78K	Hold	65	–	–	﹤0.01%	5479
2022 Q3	$50K	Hold	65	–	–	﹤0.01%	5351
2022 Q2	$203K	Hold	65	–	–	﹤0.01%	5021
2022 Q1	$267K	Buy	+65	New	+$430K	﹤0.01%	5039
2021 Q4	–	Hold	0	–	–	–	5675

Other funds holding ENSC

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

TIAM2

Tru Independence Asset Management 2 Portland, Oregon $185M AUM 20.3% 1-Year Est. Return

BlackRock's ENSC Position: Q2 2026 in Review

BlackRock held its Ensysce Biosciences (ENSC) position steady in Q2 2026 at 65 shares worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #5659.

BlackRock first reported a position in ENSC in Q1 2022 and has held it in 18 quarters since. The position peaked at $267K in Q1 2022. 18 funds tracked by Wall St. Rank hold ENSC as of Q2 2026.

BlackRock held 65 shares of Ensysce Biosciences worth $19 as of Q2 2026.
BlackRock left its Ensysce Biosciences share count unchanged in Q2 2026.
Ensysce Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5659 holding.
BlackRock first reported a position in Ensysce Biosciences in Q1 2022 and has held it in 18 quarters since.
BlackRock's Ensysce Biosciences position peaked at $267K in Q1 2022.
18 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.